ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
- Extends Series A with additional EUR19 million led by Fund+
- Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials
- XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in the future
News provided by
Share this article
Share this article
GHENT, Belgium, March 16, 2021 /PRNewswire/ ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million. The financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.